Effect of tandospirone on tardive dyskinesia and parkinsonian symptoms

K Yoshida; T Sugita; H Higuchi; Y Hishikawa

doi:10.1016/S0924-9338(99)80690-7

Summary

The authors examined the effect of tandospirone on tardive dyskinesia (TD) and parkinsonian symptoms in an open study. Tandospirone did not bring about any favourable effect on TD, but it had a good effect on the parkinsonian symptoms.

References

Goff, DCMidha, KKBrotman, AWMcCormick, SWaites, MAmico, ETAn open trial of buspirone added to neuroleptics in schizophrenic patients J Clin Psychopharmacol 1991; 11: 193–197CrossRef Google Scholar PubMed

Haggstrom, JEGunne, LMCarlsson, AWikstrom, HAntidyskinetic action of 3-PPP, a selective dopaminergic autoreceptor agonist, in Cebus monkeys with persistent neuroleptic-induced dyskinesias J Neural Transm 1983; 58: 135–142CrossRef Google Scholar PubMed

Hamik, AOksenberg, DFischette, CPeroutka, SJAnalysis of tandospirone (SM-3997) interactions with neurotransmitter receptor binding sites Biol Psychiatry 1990; 28: 99–109CrossRef Google Scholar PubMed

Kapur, SRemington, GSerotonin-dopamine interaction and its relevance to schizophrenia Am J Psychiatry 1996; 153: 466–476Google Scholar

McMillen, BAComparative chronic effects of buspirone or neuroleptics on rat brain dopaminergic neurotransmission J Neural Transm 1985; 64: 1–12CrossRef Google Scholar PubMed

Moss, LENeppe, VMDrevets, WCBuspirone in the treatment of tardive dyskinesia J Clin Psychopharmacol 1993; 13: 204–209CrossRef Google Scholar PubMed

Riblet, LATaylor, DPEison, MSStanton, HCPharmacology and neurochemistry of buspirone J Clin Psychiatry 1982; 43: 11–18Google Scholar PubMed

Schooler, NRKane, JMResearch diagnoses for tardive dyskinesia [letter] Arch Gen Psychiatry 1982; 39: 486–487Google Scholar

Crossref Citations

This article has been cited by the following publications. This list is generated based on data provided by Crossref.

Prinssen, E.P.M. Koek, W. Colpaert, F.C. and Kleven, M.S. 2000. Repeated treatment with 8-OH-DPAT induces tolerance to its ability to produce the 5-HT1A behavioural syndrome, but not to its ability to attenuate haloperidol-induced catalepsy. Behavioural Pharmacology, Vol. 11, Issue. 3 & 4, p. 299.

Prinssen, Eric P.M Koek, Wouter and Kleven, Mark S 2000. Effects of WAY 100635 on antipsychotic-induced catalepsy in 5-HT depleted animals: a role for tonic activation of 5-HT1A receptors. European Journal of Pharmacology, Vol. 395, Issue. 2, p. 143.

Miyata, Shinji Hamamura, Takashi Yoshinaga, Junji Nakamura, Yasushi Imamura, Takaki Hikiji, Akiyoshi and Kuroda, Shigetoshi 2001. Amelioration of Frozen Gait by Tandospirone, a Serotonin 1A Agonist, in a Patient with Pure Akinesia Developing Resistance to L-threo-3,4-dihydroxyphenylserine. Clinical Neuropharmacology, Vol. 24, Issue. 4, p. 232.

Deshpande, Laxmikant S. Khisti, Rahul T. and Chopde, Chandrabhan T. 2001. Cataleptic effect of neurosteroid 3α-hydroxy-5α-pregnan-20-one in mice: modulation by serotonergic agents. Brain Research, Vol. 898, Issue. 1, p. 13.

Depoortere, Ronan Boulay, Denis Perrault, Ghislaine Bergis, Olivier Decobert, Michel Françon, Dominique Jung, Mireille Simiand, Jacques Soubrié, Philippe and Scatton, Bernard 2003. SSR181507, A Dopamine D2 Receptor Antagonist and 5-HT1A Receptor Agonist. II: Behavioral Profile Predictive of an Atypical Antipsychotic Activity. Neuropsychopharmacology, Vol. 28, Issue. 11, p. 1889.

Chu, Wenhua Tu, Zhude McElveen, Elizabeth Xu, Jinbin Taylor, Michelle Luedtke, Robert R. and Mach, Robert H. 2005. Synthesis and in vitro binding of N-phenyl piperazine analogs as potential dopamine D3 receptor ligands. Bioorganic & Medicinal Chemistry, Vol. 13, Issue. 1, p. 77.

Bantick, R. Alexander De Vries, Michiel H. and Grasby, Paul M. 2005. The effect of a 5-HT1A receptor agonist on striatal dopamine release. Synapse, Vol. 57, Issue. 2, p. 67.

Assié, Marie-Bernadette Dominguez, Hélène Consul-Denjean, Nathalie and Newman-Tancredi, Adrian 2006. In vivo occupancy of dopamine D2 receptors by antipsychotic drugs and novel compounds in the mouse striatum and olfactory tubercles. Naunyn-Schmiedeberg's Archives of Pharmacology, Vol. 373, Issue. 6, p. 441.

Zazpe, Arturo Artaiz, Inés Innerárity, Ana del Olmo, Elena Castro, Elena Labeaga, Luis Pazos, Angel and Orjales, Aurelio 2006. In vitro and in vivo characterization of F-97013-GD, a partial 5-HT1A agonist with antipsychotic- and antiparkinsonian-like properties. Neuropharmacology, Vol. 51, Issue. 1, p. 129.

Bardin, Laurent Kleven, Mark S Barret-Grévoz, Catherine Depoortère, Ronan and Newman-Tancredi, Adrian 2006. Antipsychotic-Like vs Cataleptogenic Actions in Mice of Novel Antipsychotics Having D2 Antagonist and 5-HT1A Agonist Properties. Neuropsychopharmacology, Vol. 31, Issue. 9, p. 1869.

Bardin, Laurent Auclair, Agnès Kleven, Mark S. Prinssen, Eric P.M. Koek, Wouter Newman-Tancredi, Adrian and Depoortère, Ronan 2007. Pharmacological profiles in rats of novel antipsychotics with combined dopamine D2/serotonin 5-HT1A activity: comparison with typical and atypical conventional antipsychotics. Behavioural Pharmacology, Vol. 18, Issue. 2, p. 103.

Auclair, Agnès L. Galinier, Alexandra Besnard, Joël Newman-Tancredi, Adrian and Depoortère, Ronan 2007. Putative antipsychotics with pronounced agonism at serotonin 5-HT1A and partial agonist activity at dopamine D2 receptors disrupt basal PPI of the startle reflex in rats. Psychopharmacology, Vol. 193, Issue. 1, p. 45.

Depoortère, R Bardin, L Auclair, A L Kleven, M S Prinssen, E Colpaert, F Vacher, B and Newman‐Tancredi, A 2007. F15063, a compound with D2/D3 antagonist, 5‐HT1A agonist and D4 partial agonist properties: (II) Activity in models of positive symptoms of schizophrenia. British Journal of Pharmacology, Vol. 151, Issue. 2, p. 253.

McCreary, Andrew C Glennon, Jeffrey C Ashby, Charles R Meltzer, Herbert Y Li, Zhu Reinders, Jan-Hendrik Hesselink, Mayke B Long, Stephen K Herremans, Arnoud H van Stuivenberg, Herman Feenstra, Rolf W and Kruse, Chris G 2007. SLV313 (1-(2,3-Dihydro-Benzo[1,4]Dioxin-5-yl)-4- [5-(4-Fluoro-Phenyl)-Pyridin-3-ylmethyl]-Piperazine Monohydrochloride): A Novel Dopamine D2 Receptor Antagonist and 5-HT1A Receptor Agonist Potential Antipsychotic Drug. Neuropsychopharmacology, Vol. 32, Issue. 1, p. 78.

Butini, Stefania Gemma, Sandra Campiani, Giuseppe Franceschini, Silvia Trotta, Francesco Borriello, Marianna Ceres, Nicoletta Ros, Sindu Coccone, Salvatore Sanna Bernetti, Matteo De Angelis, Meri Brindisi, Margherita Nacci, Vito Fiorini, Isabella Novellino, Ettore Cagnotto, Alfredo Mennini, Tiziana Sandager-Nielsen, Karin Andreasen, Jesper Tobias Scheel-Kruger, Jorgen Mikkelsen, Jens D. and Fattorusso, Caterina 2009. Discovery of a New Class of Potential Multifunctional Atypical Antipsychotic Agents Targeting Dopamine D3 and Serotonin 5-HT1A and 5-HT2A Receptors: Design, Synthesis, and Effects on Behavior. Journal of Medicinal Chemistry, Vol. 52, Issue. 1, p. 151.

Ellenbroek, Bart A. 2012. Psychopharmacological treatment of schizophrenia: What do we have, and what could we get?. Neuropharmacology, Vol. 62, Issue. 3, p. 1371.

Cappelli, Andrea Manini, Monica Valenti, Salvatore Castriconi, Federica Giuliani, Germano Anzini, Maurizio Brogi, Simone Butini, Stefania Gemma, Sandra Campiani, Giuseppe Giorgi, Gianluca Mennuni, Laura Lanza, Marco Giordani, Antonio Caselli, Gianfranco Letari, Ornella and Makovec, Francesco 2013. Synthesis and structure–activity relationship studies in serotonin 5-HT1A receptor agonists based on fused pyrrolidone scaffolds. European Journal of Medicinal Chemistry, Vol. 63, Issue. , p. 85.

Meadows, Samantha M. Chambers, Nicole E. Conti, Melissa M. Bossert, Sharon C. Tasber, Crystal Sheena, Eitan Varney, Mark Newman-Tancredi, Adrian and Bishop, Christopher 2017. Characterizing the differential roles of striatal 5-HT 1A auto- and hetero-receptors in the reduction of l -DOPA-induced dyskinesia. Experimental Neurology, Vol. 292, Issue. , p. 168.

Huang, Xuefei Yang, Jing Yang, Sijin Cao, Shousong Qin, Dalian Zhou, Ya Li, Xiaoli Ye, Yun and Wu, Jianming 2017. Role of tandospirone, a 5-HT1A receptor partial agonist, in the treatment of central nervous system disorders and the underlying mechanisms. Oncotarget, Vol. 8, Issue. 60, p. 102705.

Lanza, Kathryn and Bishop, Christopher 2018. Serotonergic targets for the treatment of l-DOPA-induced dyskinesia. Journal of Neural Transmission, Vol. 125, Issue. 8, p. 1203.

Download full list

Article contents

Effect of tandospirone on tardive dyskinesia and parkinsonian symptoms

Summary

Keywords

Access options

References

Comments

This article has been cited by the following publications. This list is generated based on data provided by Crossref.

Article contents

Effect of tandospirone on tardive dyskinesia and parkinsonian symptoms

Summary

Keywords

Access options

References

Comments

Save article to Kindle

Save article to Dropbox

Save article to Google Drive

Reply to: Submit a response

Your details

You have entered the maximum number of contributors

Conflicting interests